M12 co-led a $22m series A round for the drug discovery technology developer with Playground Global, and both investors have taken board seats.
US-based drug development technology developer 1910 Genetics emerged from stealth yesterday having completed a $22m series A round featuring software producer Microsoft’s corporate venturing unit, M12.
Venture capital firm Playground Global co-led the round, which followed a $4.1m seed round led by Sam Altman and backed by fellow angel investors including Tuck Lye Koh as well as FoundersX Ventures, Y Combinator, Scientia Ventures and Emles Advisors.
Founded in 2018, 1910 has developed technology that applies artificial intelligence to the development…
